The four ways to pay for a GLP-1 in 2026

The price of these medicines changed more in the last year than in the four years before it. If you last checked in 2025, your information is out of date.

There are now four routes. The cheapest one depends entirely on who you are, and for a lot of people the cheapest route is one they have never heard of.

Check this before you buy anything, including from us. If you qualify for a fifty dollar programme, we would rather you use it.

The four routes at a glance

Route 1: Medicare, if you qualify

CMS runs a demonstration called the Medicare GLP-1 Bridge. It gives eligible Medicare Part D beneficiaries certain GLP-1 drugs for a flat fifty dollars a month, running 1 July 2026 to 31 December 2027.

The products CMS names are Foundayo, Wegovy in injection and tablet form, and Zepbound KwikPen.

To qualify you must be enrolled in a standalone Part D prescription drug plan, or a Medicare Advantage plan that includes drug coverage, in the current plan year. CMS directs people to check eligibility at Medicare.gov.

The fine print, which almost nobody prints:

• Your Part D deductible does not apply.
• The fifty dollars does not count toward your true out of pocket total, so it does not move you toward the catastrophic phase of your Part D benefit.
• There is no low income subsidy attached to it.
• It operates outside the normal Part D benefit flow, so your plan carries no risk and did not have to opt in.

None of that makes it a bad deal. It makes it a different kind of deal, and if you are managing other drug costs across the year, those three points matter.

Coming next. A successor programme called BALANCE begins for Medicare Part D on 1 January 2027 and runs to the end of 2031, with state Medicaid agencies able to join from May 2026. Under it, CMS negotiates GLP-1 pricing on behalf of Part D plans and state Medicaid agencies, and participating Part D plans must cap patient cost at fifty dollars per monthly supply in the initial coverage phase.

Route 2: Commercial insurance

If your employer or marketplace plan covers weight management medicines, this is frequently the cheapest route, and it is also the most variable.

Two things to establish:

Does your plan cover the indication? Many plans cover a GLP-1 for type 2 diabetes but not for weight management. The same molecule under a different brand can be covered or not covered, which is why the Ozempic and Wegovy distinction matters more than it sounds.

Is prior authorisation required? Usually yes for weight management. That means documentation from your clinician before the plan will pay.

A denial is not always the end. Plans have appeal processes, and the criteria are usually published.

Route 3: TrumpRx.gov, the federal cash price

The federal government launched TrumpRx.gov on 6 February 2026 as a direct to patient purchasing website, following most favoured nation pricing agreements with several manufacturers.

Understand what it is. It is not a pharmacy and it does not prescribe. You need a valid prescription you already hold. The site gives you a coupon, which you can print or keep on your phone, and you buy at a participating pharmacy.

Prices published by the White House at launch:

At launch the site covered around 40 branded medicines from five manufacturers, across GLP-1s, fertility, respiratory inhalers, dermatology, hormone replacement and insulin. It excludes controlled substances and drugs subject to certain federal safety programmes, which does not affect GLP-1s but does affect other categories people ask about.

This route is generally the best option for someone with no coverage who wants an FDA approved product.

Route 4: Compounded

Still the lowest sticker price, and the only one of the four that is not an FDA approved product.

The large scale legal basis for compounding these two molecules ended across 2025 when the FDA determined the shortages were resolved. Products are still sold under a narrower argument about personalisation. We cover that in detail separately, along with what the comparative evidence shows, which is thin and does not favour the compounded version.

The honest point for this page is narrower: compounded used to be dramatically cheaper than everything else, and in 2026 it is competing against a fifty dollar Medicare copay and a $149 to $350 cash price for reviewed products. The gap that justified the trade off is much smaller than it was.

How to work out your own answer

In this order.

1. Are you on Medicare Part D? Check the GLP-1 Bridge first. Fifty dollars is hard to beat.
2. Do you have commercial insurance? Call the number on the card and ask whether weight management medicines are covered, and whether prior authorisation is needed. Ask about the specific brand.
3. Neither? Check the TrumpRx price for the specific product you want.
4. Only then compare a compounded offer, knowing it is not an FDA approved product.

Compare the total, not the sticker

Whichever route, ask the same questions:

• What is the cost at my target dose, not the starting dose?
• Does the price change as I titrate up?
• Is there a membership, consultation or subscription fee on top of the medicine?
• What happens to the price after any introductory period?
• How do I cancel, and how many steps is it?

That last one is where a lot of real complaints live. In December 2025 the Federal Trade Commission finalised an order against a telehealth weight loss provider requiring clear disclosure of refund and cancellation terms before a consumer is asked to pay, a simple way to cancel, and prompt honouring of cancellations. In July 2026 the FTC and two states filed a case alleging a telehealth company enrolled people in recurring subscriptions on submitting an intake form and hid the cancellation button.

One more thing, before cost decides it

These medicines are not a short course. A meta-analysis of 11 studies covering 12,539 people found that after stopping a high dose GLP-1, 50 to 65 percent of the weight lost returned within twelve months, most of it in the first three to six.

So the number that matters is not the first month. It is what you can sustain.

What to ask

• Am I eligible for the Medicare GLP-1 Bridge, and have I checked at Medicare.gov?
• Does my plan cover this indication, and does it need prior authorisation?
• What is the TrumpRx price for the exact product I want?
• What is my total monthly cost at target dose, including every fee?
• How do I cancel?

Sources

• Centers for Medicare and Medicaid Services, Medicare GLP-1 Bridge
• Centers for Medicare and Medicaid Services, BALANCE Model
• The White House, Fact Sheet on the launch of TrumpRx.gov, 6 February 2026
• Executive Order, Delivering Most-Favored-Nation Prescription Drug Pricing, 12 May 2025
• FDA, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize"
• Federal Trade Commission, final order concerning a telehealth provider and GLP-1 weight loss advertising, December 2025
• Federal Trade Commission and the states of Utah and California, complaint concerning a telehealth provider's privacy and billing practices, July 2026
• Weight regain after discontinuation of high dose GLP-1 receptor agonists, meta-analysis of 11 studies, 2026

How we verify: see /how-we-verify.

Keep reading

What the Medicare GLP-1 Bridge is and whether you qualify, at /guides/medicare-glp1-bridge.

What a GLP-1 costs with no insurance at all, at /guides/glp1-without-insurance.